On Monday, 23 September, the Tavapadon team presented a poster highlighting the Tavapdon Phase 2 study data in early Parkinson's Disease at the International Congress of Parkinson’s Disease and Movement Disorders in Nice, France.  Download the poster below. Objective: To evaluate the efficacy and safety of tavapadon (formerly known as PF-06649751) in subjects with early [...]